Author: Nataliia Lopina, Director and Founder, ClinCaseQuest
Presently, oncology stands as the second leading cause of mortality globally, following cardiovascular diseases. Substantial strides have been achieved in managing various oncological conditions, largely attributed to the advancements in targeted therapy for cancer. However, a noteworthy concern arises as the cardiovascular risk escalates significantly in cancer patients undergoing chemotherapy or targeted therapy, surpassing that of the general population. This heightened risk stems from increased survival rates among cancer patients and the adverse effects associated with chemotherapy and targeted treatments.
Along with the increased survival of patients with different types of oncology, special attention has recently been paid to cardiovascular complications due to the prevalence of cardiovascular diseases in the general population and the toxicity profile of targeted drugs.
Current data confirm the increased cardiovascular risk in the specific types of cancers population compared to the general population, which necessitates the widespread introduction of cardiovascular prevention strategies in such groups of patients.
Complete Article: Reducing Cardiovascular Risks in Patients with Cancer
Comments
0 comment